Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Gilead Sciences and Merck Initiate Phase 2 Study Evaluating Lenacapavir and Islatravir for HIV-1

October 26, 2021 0

Gilead Sciences and Merck Collaboration to Develop Long-Acting HIV Treatment Gilead Sciences (GILD) and Merck (MRK) …

Bausch + Lomb and Clearside Biomedical: FDA Approved XIPERE™ for Macular Edema Associated with Uveitis

October 25, 2021 0

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ Bausch + Lomb, a leading …

Agenus Strategic Decision to Withdraw the BLA for Balsitilimab

October 22, 2021 0

Agenus to Withdraw BLA for Balstilimab Agenus (AGEN) announced a strategic decision to withdraw its Biologics …

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001 See Also: Important News from Ultragenyx Pharmaceutical

October 21, 2021 0

Intellia Therapeutics Granted Orphan Drug Designation for NTLA-2001 Intellia Therapeutics (NTLA) announced that the U.S. FDA has …

Reata Pharmaceuticals Announces Presentations Highlighting Clinical Data for Bardoxolone and Disease Education Data on Alport syndrome

October 21, 2021 0

Reata Pharmaceuticals Announcements Reata Pharmaceuticals (RETA) announced that the abstracts highlighting clinical data for bardoxolone methyl …

Rocket Pharmaceuticals Inc Announces Data Updates at the ESGCT Conference for RP-L201 for the Treatment of LAD-I

October 20, 2021 0

Rocket Pharmaceuticals Inc Announces Successful Results at the ESGCT Gene therapy and gene editing plus other …

The U.S. FDA Approved Oyster Point Pharma Inc Product TYRVAYA™ to Treat Dry Eye Disease

October 18, 2021 0

Oyster Point Pharma, Inc. The U.S. Food and Drug Administration (FDA) has approved the Oyster Point Pharma Inc …

Intellia Therapeutics and SparingVision Strategic Collaboration to Develop Novel Ocular Therapies. See Also: Crispr Therapeutics’ News is Good, Not Bad

October 14, 2021 0

Intellia Therapeutics and SparingVision Collaboration Intellia Therapeutics (NTLA) and SparingVision - a genomic medicine company developing …

Regenxbio Good News About RGX-314 for Diabetic Retinopathy

October 11, 2021 0

Regenxbio Announced Data from Phase 2 ALTITUDE Trial of RGX-314 for DR Regenxbio (RGNX) announced initial …

Don’t Miss the Enanta Pharmaceuticals Virtual Conference on October 19th – October 21st

October 11, 2021 0

Don’t Miss Enanta Pharmaceuticals Virtual Conference Enanta Pharmaceuticals (ENTA) – a clinical stage biotechnology company dedicated …

Denali Therapeutics: Positive Clinical Results and Regulatory Progress for Development Programs in ALS. See Also: NTLA Tumbling Today

October 8, 2021 0

Denali Therapeutics News Denali Therapeutics (DNLI) - a biopharmaceutical company developing a broad portfolio of product …

Intellia Therapeutics: Authorized to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for Hereditary Angioedema

October 6, 2021 0

Intellia Therapeutics Authorization of CTA for Phase 1/2 Study of NTLA-2002 Intellia Therapeutics (NTLA) announced the …

Atea Pharmaceuticals and Xenon Pharmaceuticals: Two Clinical-Stage Firms That Rallied Instead of Crashing Yesterday

October 5, 2021 0

Two Clinical-Stage Firms Rallied Yesterday On a day when the Stock Market was crushed, taking down …

Merck and Ridgeback Biotherapeutics Announced Successful Phase 3 Trial Results of Molnupiravir for Mild or Moderate COVID-19

October 1, 2021 0

Merck and Ridgeback Biotherapeutics COVID-19 News Merck (MRK) and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801) …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Gilead Sciences and Merck Initiate Phase 2 Study Evaluating Lenacapavir and Islatravir for HIV-1

Bausch + Lomb and Clearside Biomedical: FDA Approved XIPERE™ for Macular Edema Associated with Uveitis

Agenus Strategic Decision to Withdraw the BLA for Balsitilimab

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001 See Also: Important News from Ultragenyx Pharmaceutical

Reata Pharmaceuticals Announces Presentations Highlighting Clinical Data for Bardoxolone and Disease Education Data on Alport syndrome

Rocket Pharmaceuticals Inc Announces Data Updates at the ESGCT Conference for RP-L201 for the Treatment of LAD-I

The U.S. FDA Approved Oyster Point Pharma Inc Product TYRVAYA™ to Treat Dry Eye Disease

Intellia Therapeutics and SparingVision Strategic Collaboration to Develop Novel Ocular Therapies. See Also: Crispr Therapeutics’ News is Good, Not Bad

Regenxbio Good News About RGX-314 for Diabetic Retinopathy

Don’t Miss the Enanta Pharmaceuticals Virtual Conference on October 19th – October 21st

Denali Therapeutics: Positive Clinical Results and Regulatory Progress for Development Programs in ALS. See Also: NTLA Tumbling Today

Intellia Therapeutics: Authorized to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for Hereditary Angioedema

Atea Pharmaceuticals and Xenon Pharmaceuticals: Two Clinical-Stage Firms That Rallied Instead of Crashing Yesterday

Merck and Ridgeback Biotherapeutics Announced Successful Phase 3 Trial Results of Molnupiravir for Mild or Moderate COVID-19

Valneva SE and Pfizer Inc Announce Further Positive Results in Preventing Lyme Disease

Reata Pharmaceuticals Plans to Submit Omaveloxolone NDA for Friedreich’s Ataxia in Q1 2022

AstraZeneca Saphnelo Approved in Japan for Adult Patients with SLE

The Time Has Come to Present Mirum Pharmaceuticals Inc

The World Health Organization Recommends Regeneron Pharmaceuticals Antibody Cocktail for COVID-19

Can Excision BioTherapeutics Inc Cure HIV?!